Effects of Cabozantinib on Human G292 Osteosarcoma Cells

Cabozantinib (CBZ) N-(4-((6,7-dimethoxyquinolin-4-yl) oxy) phenyl)-N-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide) (XL184), an inhibitor of MET and vascular endothelial growth factor receptor (VEGFR-2), is agent approved for the treatment several types carcinoma such as medullary thyroid renal. Recent studies are encouraging effectiveness CBZ in osteosarcoma. Because complex nature microenvironment osteosarcoma cell sites, order to better understand direct effects on cells, vitro were conducted with human line, G292. Experiments focused metabolic activity, differentiation, apoptosis well modulation responses factors platelet-derived (PDGF) insulin like (IGF-I). The results indicate that can increase activity caspase 3/7 indicator decrease cellular measured by MTT assay differentiation assessed alkaline phosphatase activity. drug partially downregulated PDGF had significant inhibitory G292 cells response IGF-I production VEGF. This study presents original information chemotherapy agent, CBZ, provides data consistent potential therapeutic this